Skip to content
Pricing
Sample Reports
Show submenu for Sample Reports
Company Report
Drug Report
Solutions
Show submenu for Solutions
Investors
Portfolio Managers
Research
Publisher Content
Resources
Show submenu for Resources
Case Studies
Demo Videos
Market Intelligence Datasets
Drug Index
FAQs
API Documentation
Company
Show submenu for Company
News & Updates
Leadership
CDD Vault
Contact Us
Login
Pricing
Sample Reports
Show submenu for Sample Reports
Company Report
Drug Report
Solutions
Show submenu for Solutions
Investors
Portfolio Managers
Research
Publisher Content
Resources
Show submenu for Resources
Case Studies
Demo Videos
Market Intelligence Datasets
Drug Index
FAQs
API Documentation
Company
Show submenu for Company
News & Updates
Leadership
CDD Vault
Contact Us
Valproate sodium
Depacon (valproate sodium) is a small molecule pharmaceutical. Valproate sodium was first approved as Depacon on 1996-12-30. It is known to target histone deacetylase 1.
Trade Name
Depacon
Common Name
Valproate sodium
Indication
Drug Class